

An Incidental Finding of Fahr's Disease In a Patient with Hypochondria.

Patricio S. Espinosa ¹, Courtland R. Samuels ², Javed Kanni ³, Kimberly Herard ⁴, Kory Barkley ⁵

1. Neurology, Marcus Neuroscience Institute - Boca Raton Regional Hospital, Boca Raton, USA 2. Emergency Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, USA 3. Medicine, FAU, Boca Raton, USA 4. Neurology, FAU, Boca Raton, USA 5. Internal Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, USA

✉ **Corresponding author:** Patricio S. Espinosa, ps.espinosa@gmail.com

Categories: Neurology

Keywords: fahr's disease

How to cite this poster

Espinosa P S, Samuels C R, Kanni J, et al. (2019) An Incidental Finding of Fahr's Disease In a Patient with Hypochondria. . Cureus 11(2): e.

Abstract

Idiopathic basal ganglia calcification (IBGC), commonly referred to as Fahr's disease, is a rare neurological disorder characterized by the abnormal, symmetrical, and bilateral calcification of the basal ganglia and other brain regions. Patients typically present in their forties and fifties with various neurologic and/or psychiatric symptoms, including movement disorders, Parkinsonism, psychosis, and depression.

The pathophysiology of this disease is not completely understood; however, several gene mutations have been identified in the pathogenesis of Fahr's disease. These mutations display an autosomal dominant inheritance pattern. Furthermore, the regional phenotypic expression of calcifications differs greatly from patient to patient, as do their clinical presentations. Here, we describe a patient who presented with psychiatric manifestations and imaging consistent with Fahr's disease.

Open Access

Published 02/14/2019

Copyright

© Copyright 2019

Espinosa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Distributed under
Creative Commons CC-BY 3.0

Introduction

Fahr's Disease, also known as idiopathic basal ganglia calcification (IBGC), or bilateral intraputamenal calcifications, is a condition characterized by calcium deposition in the brain, most often the basal ganglia. Typical presentation occurs in early or middle adulthood with neurologic or psychiatric features [1]. A wide variety of symptoms have been documented, with parkinsonism being the most common [2]. Other reported symptoms include negative impairment, ataxia, dysarthria, tremor, vertigo, hallucinations, delusions, anxiety, and depression [1]. Computed tomography (CT) scan of the brain is the most useful aid in diagnosis, and typically reveals bilateral calcification in the basal ganglia. Other structures commonly involved include the dentate nucleus, thalamus, and white matter [3]. Magnetic Resonance Imaging (MRI) has been shown to display T2-weighted hyperintensities that are believed to be related to an underlying progressive metabolic or inflammatory process. It has been suggested that the progressive process is responsible for the neurological features seen in the disease, and the calcification typically noted on CT scan is a later consequence [4]. Fetal and non-fetal forms of Fahr's Disease exist, with fetal forms inherited as an autosomal dominant trait [5]. Although the mechanism has yet to be elucidated, a number of genes have been identified, including *SLC6A12* and *PDGFRA* [6,7]; here, we describe the case of a patient who presented with psychiatric manifestations, leading to the incidental diagnosis of Fahr's Disease.

Case Description

A 47-year-old Caucasian male with a past medical history of uncontrolled diabetes mellitus, hypertension, patellofemoral reflux disease, and anxiety presented to the emergency department with a chief complaint of right foot swelling. The patient reported that the swelling started two weeks prior to presentation, but denied any associated pain. The patient denied injury or trauma to the foot. An X-ray of the right foot revealed soft tissue distention, but no evidence of an acute osseous lesion. A lower extremity doppler ultrasound was performed and ruled out the presence of a deep vein thrombosis (DVT). The patient also endorsed fatigue, dizziness and urinary retention over the previous day, but otherwise related placement of a catheter. When the patient was told that he would be discharged from the emergency department to begin continuing chest physicals, thoracic x-rays and scans, all of which he denied on review of symptoms during the initial evaluation. He stated that the chest discomfort had been present all day, was non-radiating, and rated a 4/10 in severity (RICE and cardiac enzymes were within normal levels). The patient was admitted for further evaluation.

During the hospitalization, the patient developed multiple additional complaints that after appropriate working, ultimately did not lead to a specific diagnosis. The patient worked with physical therapy and occupational therapy, who established that the patient was difficult to assess as his functional mobility issues were inconsistent. He was unable to bear weight in bilateral adductors and safety equipment, which affected the patient's ability to perform activities of daily living. Of note, one of the physical therapists documented that the patient was inebriated since in his room, walking without difficulty while leaning on his phone.

On hospital day four, the patient was discharged when told that he was being discharged, as he desired further work up for his complaints. While preparing to leave, he had an unexplained fall in his room. The patient stated that he hit his head and was in pain, but was unable to localize the pain. There was no evidence of acute trauma or physical exam. Subsequent to the fall, a formal computed tomography (CT) scan of the brain without contrast to rule out any acute intracranial trauma. Incidentally, the CT scan revealed bilateral symmetric calcifications of the basal ganglia, dentate nucleus, thalamus, dentate nucleus of cerebellum and cerebral white matter, consistent with Fahr's Disease (Figure 1). Laboratory values, such as parathyroid hormone (PTH), thyroid stimulating hormone (TSH), T4, T4U, T4 free, all within the normal reference limits. Serum calcium was mildly decreased, ranging from 8.1 - 8.4 mg/dL during the admission. After being informed of the CT scan finding, the patient revealed that his deceased mother suffered from a rare diagnosis. Further investigation, with the patient's permission, revealed a prior CT scan with similar calcifications in the basal ganglia and cerebellum, consistent with Fahr's Disease.




FIGURE 1. CT images displaying calcifications of the basal ganglia and cerebellum.
 A. Axial CT image showing bilateral linear calcifications of the basal ganglia and cerebellum.
 B. Axial CT image showing bilateral calcifications of the putamen and the head and tail of the caudate nucleus.
 C. Coronal CT image showing bilateral calcifications of the caudate nucleus and putamen.
 D. Coronal CT image showing bilateral calcifications of the putamen.
 E. Sagittal CT image showing calcification of the head of the caudate nucleus.
 F. Sagittal CT image showing calcifications throughout the basal ganglia and cerebellum.

Criteria for the diagnosis of Fahr's Disease

1. Bilateral calcification of the basal ganglia on neuroimaging or other brain region.
 2. Progressive neurological dysfunction and/or neuropsychiatric manifestations.
 3. Age of onset is typically the fourth or fifth decade, may be present also earlier in life.
 4. Absence of biochemical abnormalities and genetic features suggestive of a mitochondrial or metabolic disease or other systemic disorder.
 5. Absence of an infectious, toxic, or traumatic cause.
 6. Family history consistent with autosomal dominant inheritance.
- Table 1.** Criteria for the diagnosis of Fahr's Disease [7]. In the presence of a positive family history or consanguinity, the diagnosis can be made in absence of bilateral calcification (criterion 1), or progressive neurologic dysfunction and neuropsychiatric manifestations (criterion 2).

Discussion

The patient's presentation met the necessary criteria for the diagnosis of Fahr's Disease (Table 1). What makes our patient's presentation unique is that he exhibited few of the commonly documented manifestations seen in the literature. At the age of 47, we would expect him to present with movement disorders as they are found in the majority of patients, with parkinsonism being the most common [1,2]. Other movement manifestations that have been reported include chorea, tremor, dystonia, gaitic, ataxic, ataxia, and dystonia [1]. In 40% of Fahr's Disease cases, the first presenting feature of basal ganglia calcification are psychiatric manifestations [1]. Depression and anxiety are the most common psychiatric findings associated with Fahr's Disease [7]. Others that have been reported in the literature include dementia, delirium, confusion, hallucinations, delusions, cataplexy, mania, panic attacks, obsessive behaviors, irritability, aggression, personality disorder and personality changes [1].

Upon presentation and during his hospital stay, our patient had multiple, fluctuating complaints. Laboratory and imaging studies completed during his admission revealed no abnormalities that could explain the patient's reported symptoms. Furthermore, he participated in behaviors that would directly oppose his lab results in both prolonging his hospital stay. Retrospectively, these occurrences have led us to believe that the patient's complaints and past abnormalities were possibly behaviors in nature and potentially the result of neuroendocrine manifestations of Fahr's disease. The patient presented in this case had a previous, self-reported diagnosis of anxiety, which was not confirmed with an evaluation by a psychiatrist during his admission. However, he exhibited several behaviors that could suggest an alternate, and/or overlapping psychiatric diagnosis, such as somatic symptom disorder, factitious disorder, or malingering.

Although specific cases of Fahr's disease do not seem to exist as autosomal dominant inheritance pattern amongst families with this disease, there are two genes that predominate in the literature, which mutations are associated with Fahr's Disease: *SLC6A12* and *PDGFRA* [6,7]. There are different theories regarding the pathogenesis of Fahr's disease. Mutations in the *SLC6A12* gene encoding the sodium phosphate transporter (PHT) can explain approximately 40% of the familial cases of Fahr's disease [8]. It is believed that mutations of PHT disrupt cellular calcium and phosphate homeostasis, leading to deposition of calcium phosphate. The *PDGFRA* gene is believed to be involved in the maintenance of the blood brain barrier. Mutations lead to alterations of permeability, resulting in calcium deposition.

Phenotypically, regional location and quantity of calcifications vary greatly among patients with Fahr's disease. In a study looking to accurately diagnose and describe the clinical and radiological characteristics of Fahr's disease, researchers found that each mutation gene was associated with a different pattern of calcifications, though there was no significant difference in classic presentations based on the gene affected [9]. To further elucidate the mechanism, more studies need to be completed on the pathophysiology of Fahr's disease. Potential studies using animal models could be completed to look at the metabolic, physiologic, and/or biologic effects of the damaged protein products associated with the already identified gene mutations.

References

1. Haidich A, et al. (2019) The clinical features of Fahr's disease. *Frontiers in Neurology*, 10: 1-17.
2. Herard K, et al. (2019) Fahr's disease. *Neurology Focus*, 16: 1-10.
3. Herard K, et al. (2019) Fahr's disease. *Neurology Focus*, 16: 1-10.
4. Herard K, et al. (2019) Fahr's disease. *Neurology Focus*, 16: 1-10.
5. Herard K, et al. (2019) Fahr's disease. *Neurology Focus*, 16: 1-10.
6. Herard K, et al. (2019) Fahr's disease. *Neurology Focus*, 16: 1-10.
7. Herard K, et al. (2019) Fahr's disease. *Neurology Focus*, 16: 1-10.
8. Herard K, et al. (2019) Fahr's disease. *Neurology Focus*, 16: 1-10.
9. Herard K, et al. (2019) Fahr's disease. *Neurology Focus*, 16: 1-10.